LTR PHARMA LIMITED

24.7%

58.0¢

Market Cap $64.93M

Healthcare Biotechnology

LTR Pharma Limited is an Australia-based clinical-stage biopharmaceutical company. The... LTR Pharma Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is developing and commercializing therapies that address significant unmet medical needs. The Company is focused on improving men’s health through clinical development and commercialization of nasal spray treatments for erectile dysfunction. Its lead products, SPONTAN and ROXUS, are fast-acting intranasal sprays for the treatment of erectile dysfunction, enabling onset of action in 10 minutes or less. The Company is also advancing OROFLOW, a novel intranasal spray under development for the treatment of Oesophageal Motility Disorders (OMD) - a debilitating group of conditions affecting swallowing function. The Company's subsidiary is LTR Pharma Inc.More

Neurizon's (ASX:NUZ) NUZ-001 OLE Study Demonstrates Long-Term Safety and Efficacy Signals

Latest Threads

Tag

Subject

LTP

Chart

2 3

12/09/25

133

34K

12/09/25

Last post Bruno81

133

34K

LTP

Ann: FY25 Results Announcement

12/09/25

5.4K

12/09/25

Last post ibuyhigh

5.4K

LTP

Ann: Appendix 4G and Corporate Governance Statement

29/08/25

119

29/08/25

Last post

ASX News

119

LTP

Ann: Appendix 4E and Annual Report to Shareholders

29/08/25

174

29/08/25

Last post

ASX News

174

LTP

Ann: 18-Month Shelf Life Strengthens SPONTAN Commercialisation

26/08/25

4.9K

26/08/25

Last post originenergysux

4.9K

LTP

Ann: SPONTAN Case Series - Strong Post-Prostatectomy Results

25/08/25

2.1K

25/08/25

Last post stevemol

2.1K

LTP

Ann: SPONTAN 5x Faster Onset Validated in EU Journal

22/08/25

2.8K

22/08/25

Last post Gordy56

2.8K

LTP

Ann: SPONTAN Final Study Results

4 5 6

20/08/25

321

128K

20/08/25

Last post chuk

321

128K

See All Discussions

Timeline

FY25 Results Announcement
29 Aug 08:49	Share

Appendix 4G and Corporate Governance Statement
29 Aug 08:49	Share

Appendix 4E and Annual Report to Shareholders
29 Aug 08:48	Share

SPONTAN Case Series - Strong Post-Prostatectomy Results
25 Aug 09:04	Share

18-Month Shelf Life Strengthens SPONTAN Commercialisation
22 Aug 09:23	Share

SPONTAN 5x Faster Onset Validated in EU Journal
20 Aug 09:15	Share

US ED Specialist Dr Sun Joins LTR Advisory Board
18 Aug 08:41	Share

US ED Specialist Dr Pearlman Joins LTR Advisory Board
11 Aug 08:39	Share

Quarterly Activities/Appendix 4C Cash Flow Report
29 Jul 08:41	Share

Proposed issue of securities - LTP
29 Jul 08:36	Share

Notification regarding unquoted securities - LTP
14 Jul 08:40	Share

LTP Completes Extractables Study Milestone for SPONTAN
30 Jun 08:32	Share

Urological Expert Appointed to LTR Scientific Advisory Board
21 May 08:22	Share

SPONTAN Expands Patient Access via National Pharmacy Network
20 May 08:27	Share

LTR Signs Collaborative Agreement to Develop OMD Nasal Spray
08 May 08:35	Share

Quarterly Activities/Appendix 4C Cash Flow Report
29 Apr 09:15	Share

Change of Registered Office Address
04 Apr 18:05	Share

Change of Company Secretary
01 Apr 09:49	Share

Investor Presentation
27 Mar 10:27	Share

Commercial Update and Regulatory Progress
26 Mar 08:58	Share

LTR Pharma to Showcase SPONTAN Data at Urology Conference
28 Feb 08:40	Share

Appendix 4D and Half Yearly Report
27 Feb 08:31	Share

Quarterly Activities/Appendix 4C Cash Flow Report
30 Jan 08:34	Share

LTR Signs Symbion National Pharmacy Distribution Agreement
22 Jan 08:40	Share

Response to ASX Query Letters
30 Dec 16:11	Share

Agreement with Men's Health Pharmacy for SPONTAN access
19 Dec 08:20	Share

Cleansing Notice
17 Dec 08:38	Share

Application for quotation of securities - LTP
17 Dec 08:37	Share

Early Launch of Online Mens Health Platform
12 Dec 08:28	Share

Change of Company Secretary
11 Dec 15:55	Share

View More

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 58.0¢		Change 0.115(24.7%)		Mkt cap ! $64.93M

Open	High	Low	Value	Volume
47.5¢	58.0¢	47.5¢	$1.630M	3.029M

Buyers (Bids)

No.	Vol.	Price($)
1	27566	58.0¢

Sellers (Offers)

Price($)	Vol.	No.
58.5¢	35000	1

View Market Depth

No.	Vol.	Price($)
1	27566	0.580
1	2500	0.575
1	1200	0.550
1	1028	0.535
1	2000	0.530

Price($)	Vol.	No.
0.585	35000	1
0.590	31921	2
0.600	5900	2
0.605	19997	1
0.610	10000	1

Last trade - 16.10pm 12/09/2025 (20 minute delay)


Last 57.5¢		Change 0.115 ( 23.7 %)
Open	High	Low	Volume
47.5¢	57.5¢	47.5¢	290511
Last updated 15.59pm 12/09/2025 ?

LTP (ASX) Chart

LTR PHARMA LIMITED

Latest Threads

Timeline

Featured News

Latest Articles

LTR Pharma dips -6% as US growth plans confuse with two identical products to be launched

LTR Pharma has revealed its latest plan to further expand into the U.S. – with a product, Roxus, it says taps into "personalised healthcare."

LTR Pharma pairs with Men's Health Downunder for supply of erectile dysfunction spray

LTR Pharma Ltd has signed an agreement with Men's Health Downunder to facilitate supply of its lead nasal spray SPONTAN

LTR Pharma launches mix of online e-store, telehealth service to boost prescriptions

LTR Pharma has launched an online 'men's health platform' to "facilitate the regulated prescription" of its nasal spray viagra product.

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News